Constipation: Laxative and Prokinetic Pharmacotherapy
Core concept: Medication selection depends on the cause and phenotype of constipation, response to prior therapy, and contraindications to laxatives, prokinetics, or peripherally acting mu-opioid receptor antagonists (Chang et al., 2023; Poole, 2026).
Key clinical distinction: Chronic idiopathic constipation, IBS-C, defecatory dysfunction, and opioid-induced constipation have overlapping symptoms but different treatment pathways.
Prescribing priority: Distinguish uncomplicated functional or idiopathic constipation from obstruction, pelvic floor dysfunction, secondary medication effects, and alarm presentations. Treat the right constipation phenotype rather than escalating laxatives indiscriminately (Chang et al., 2023; Poole, 2026).
Recognition and Diagnostic Boundaries
Constipation may involve hard stool, excessive straining, sensation of incomplete evacuation or outlet blockage, infrequent spontaneous bowel movements, or reliance on rescue interventions. Frequency alone is not diagnostic. Clarify duration, baseline habit, stool form, rectal bleeding, abdominal pain, fecal incontinence, and use of opioids, anticholinergics, iron, calcium, and other constipating agents (Poole, 2026).
Rome V now calls the adult disorder chronic constipation rather than functional constipation. In the absence of sufficient IBS criteria, diagnosis includes at least two symptoms such as hard stools, straining, incomplete evacuation, outlet blockage, manual maneuvers, or fewer than three spontaneous bowel movements weekly; loose stools rarely occur without laxatives. Criteria apply during the past three months, with symptom onset at least six months before diagnosis. Pediatric labeled functional constipation is a separate indication and should not be reinterpreted as the adult Rome V category (Rome Foundation, 2026).
Rectal bleeding, iron deficiency anemia, unintentional weight loss, or relevant family cancer history warrant evaluation beyond empiric laxatives. Severe pain, vomiting, or distension raises concern for obstruction and requires urgent assessment. Refractory straining with soft stool suggests a defecatory disorder; anorectal evaluation and pelvic-floor biofeedback can be more appropriate than repeated secretagogue trials (Poole, 2026).
Treatment Pathways by Clinical Phenotype
| Phenotype | First decisions | Escalation |
|---|---|---|
| Mild or uncomplicated chronic idiopathic constipation (CIC) | Assess medicines, physical activity, access to toilets, hydration, dietary fiber; consider psyllium especially if low fiber intake. PEG is a strongly recommended OTC option. | Measure weekly spontaneous bowel movements and straining after an adequate trial; tailor adherence and side effects. |
| CIC insufficiently responsive to OTC therapy | Consider linaclotide, plecanatide, or prucalopride (strong AGA–ACG recommendations); lubiprostone is conditional. | Consider diarrhea risk, cost/access, specific contraindications, and the underlying defecation mechanism. |
| Opioid-induced constipation (OIC) | Use scheduled traditional laxatives first; consider stimulant plus osmotic strategy, and review opioid benefit/alternatives. | In laxative-refractory OIC, guidelines favor naldemedine or naloxegol; methylnaltrexone is another option. |
| Suspected fecal impaction | Evaluate for obstruction, rectal stool burden, and overflow diarrhea; use appropriate disimpaction strategy. | Do not assume watery seepage excludes constipation. |
| Pediatric functional constipation | Assess age, impaction, and organic warning signs; individualize education and age-appropriate toileting. High-dose PEG or enemas are disimpaction options; PEG is strongly recommended for maintenance (Gordon et al., 2026). | Check age- and indication-specific label for newer agents; do not copy adult CIC dosing into a child. |
Pharmacologic Class Comparison
| Class | Mechanism and role | Important cautions |
|---|---|---|
| Bulk-forming fiber (psyllium) | Water-retaining gel increases stool bulk; useful in some low-fiber adults. | Bloating; requires adequate fluid, unsuitable in suspected obstruction or swallowing difficulty without appropriate precautions. |
| Osmotic agents (PEG, lactulose) | Retain luminal water; PEG has a strong evidence-based role in adult CIC. | Bloating or loose stool; assess renal status and electrolyte risks separately before considering magnesium- or phosphate-containing products. |
| Stimulants (bisacodyl, senna) | Enhance colonic secretion and motility; bisacodyl/sodium picosulfate strong for short-term or rescue use. | Cramps/diarrhea; evaluate longer-term need and alternative diagnoses. |
| Stool softeners (docusate) | Surfactant effect; sometimes used when minimizing straining. | Docusate was not included among AGA–ACG guideline-recommended pharmacologic options for adult CIC; avoid substituting it for more strongly supported treatments when symptoms persist (Chang et al., 2023). |
| Secretagogues (lubiprostone, linaclotide, plecanatide) | Increase intestinal fluid secretion and improve transit in approved indications. | Avoid in known/suspected mechanical obstruction; diarrhea and dehydration risks. Indication-specific ages and doses differ. |
| 5-HT4 prokinetic (prucalopride) | Promotes coordinated colonic motility in adult CIC. | Check renal function, obstruction contraindications, and mood changes or emergent suicidal thoughts. |
| PAMORAs (naldemedine, naloxegol, methylnaltrexone) | Block peripheral opioid-mediated gut dysmotility while generally preserving central analgesia. | Mechanical obstruction/perforation risk, potential withdrawal, and medication-specific CYP interactions. |
Guideline Strength Affects First-Line Selection
The 2023 AGA–ACG guideline strongly recommends PEG for adult CIC. Bisacodyl/sodium picosulfate is strongly recommended for short-term or rescue treatment; linaclotide, plecanatide, and prucalopride have strong recommendations for adults not responding to OTC treatment. Fiber, lactulose, magnesium oxide, senna, and lubiprostone have conditional recommendations. The guideline addresses CIC in adults, not IBS-C or OIC (Chang et al., 2023).
Docusate is not among the guideline-recommended drug options. This is a useful prescribing discriminator: a familiar drug with a favorable reputation is not automatically an effective monotherapy for chronic symptoms (Chang et al., 2023).
Representative Adult Regimens and Prescribing Limits
| Drug | Example adult regimen | Clinical nuance |
|---|---|---|
| Polyethylene glycol 3350 | 17 g powder orally once daily for occasional constipation; longer-term CIC use is guideline-supported with clinician oversight. | Confirm formulation, adequate fluid intake, and expected onset (often 1–3 days). |
| Linaclotide | CIC: 145 mcg orally daily; 72 mcg daily may be used for tolerability. IBS-C: 290 mcg daily. | Take at least 30 minutes before a meal on an empty stomach; severe diarrhea requires reassessment. Separate pediatric indications follow a different schedule. |
| Plecanatide | 3 mg orally once daily in approved adult constipation indications. | Monitor diarrhea and hydration; do not extrapolate adult labels to pediatric patients. |
| Lubiprostone | CIC: 24 mcg orally twice daily with food and water; IBS-C: 8 mcg twice daily in adult women. | Hepatic impairment may require adjustment. Nausea, diarrhea, dyspnea and hypotension can limit treatment. |
| Prucalopride | 2 mg orally daily for adult CIC; 1 mg daily with creatinine clearance below 30 mL/min. | Avoid in intestinal obstruction; monitor for mood or behavioral changes. |
| Naldemedine | 0.2 mg orally once daily for eligible adults with OIC. | Check contraindications and interactions; this is not a routine treatment for CIC. |
These examples are not interchangeable. Verify the precise diagnosis, route, age, renal/hepatic status, manufacturer label, bowel obstruction risk, and medication interactions (Chang et al., 2023; Poole, 2026; Allergan, Inc., 2026).
Pediatric Age-and-Indication Corrections
The current May 2026 Linzess label includes the following age-specific U.S. indications: functional constipation for children age 2 or older (72 mcg daily), and IBS-C for patients age 7 or older (145 mcg daily), compared with adult IBS-C dosing of 290 mcg daily. Linaclotide remains contraindicated below age 2 because of the risk of serious dehydration. These FDA-labeled indications are product-specific (U.S. Food and Drug Administration, 2026), not a recommendation to bypass conventional pediatric constipation treatment (Allergan, Inc., 2026).
Behavioral withholding, painful defecation, and fecal impaction are common pediatric considerations. Evaluate delayed meconium, failure to thrive, neurologic abnormalities, severe distension, and other organic red flags. The 2026 ESPGHAN/NASPGHAN guideline supports individualized education and age-appropriate toileting, prioritizes disimpaction when needed, and strongly recommends PEG for pediatric functional constipation maintenance. It conditionally suggests linaclotide but does not suggest prucalopride; clinical recommendations and U.S. pediatric indications are separate decisions (Gordon et al., 2026).
Opioid-Induced Constipation: A Distinct Treatment Algorithm
Opioid activation of enteric mu receptors reduces peristalsis and secretions. Traditional laxatives remain first-line, but laxative-refractory OIC calls for pharmacotherapy directed at peripheral opioid receptors. The AGA guideline strongly recommends naldemedine and naloxegol after inadequate laxative response and conditionally suggests methylnaltrexone. It made no recommendation for lubiprostone or prucalopride specifically in OIC owing to evidence gaps; do not confuse that with lubiprostone having its own FDA OIC indication (Crockett et al., 2019).
Before PAMORA therapy, exclude bowel obstruction, review gastrointestinal wall-integrity risk (such as active ulcers or infiltrative disease), check interacting medications, and explain potential cramping, diarrhea and opioid withdrawal. Continue to assess the underlying opioid regimen and functional response (Crockett et al., 2019; Poole, 2026).
PAMORA Prescribing: Product-Specific Dose and Interaction Differences
| Agent / usual adult OIC regimen | Renal / interaction decision | Major exclusions and safeguards |
|---|---|---|
| Naloxegol: 25 mg orally each morning on an empty stomach; may use 12.5 mg if not tolerated. | Start 12.5 mg daily if CrCl <60 mL/min. Strong CYP3A4 inhibitors (e.g., clarithromycin) contraindicated; moderate inhibitors usually avoid (if unavoidable 12.5 mg daily); avoid grapefruit. | Known/suspected or recurrent bowel obstruction; avoid severe hepatic impairment; assess withdrawal and perforation signs. |
| Naldemedine: 0.2 mg orally once daily with or without food. | Avoid strong CYP3A inducers (e.g., rifampin). Monitor increased adverse reactions with moderate/strong inhibitors and P-gp inhibitors; do not substitute naloxegol interaction rules. | Known/suspected obstruction or risk of recurrence; assess GI-wall injury, withdrawal, worsening pain; stop when opioid discontinued. |
| Methylnaltrexone: 450 mg orally each morning OR 12 mg SC daily for chronic noncancer pain. | CrCl <60 mL/min: 150 mg orally or 6 mg SC daily for chronic noncancer pain. Hepatic adjustments vary by formulation. | Only SC formulation is also indicated for OIC in advanced illness (different weight-/frequency-based schedule); avoid obstruction and monitor perforation/withdrawal risk. |
Prescribing-label source note: Consult the indication-specific U.S. product labels cited in the references (BioDelivery Sciences International, Inc., 2025; Averitas Pharma, Inc., 2026; Salix Pharmaceuticals, Inc., 2024a); verify the current formulation, dose, warnings and population before use.
A patient receiving clarithromycin and extended-release opioids should not automatically receive naloxegol: the CYP3A4 interaction is a contraindication, not simply a reason to monitor. Switching to naldemedine still requires reviewing CYP3A and P-glycoprotein modifiers and obstruction risk. In advanced illness, do not copy the methylnaltrexone chronic noncancer-pain schedule into the palliative-care injection indication (BioDelivery Sciences International, Inc., 2025; Averitas Pharma, Inc., 2026; Salix Pharmaceuticals, Inc., 2024a).
Pediatric GC-C agonists also need drug-specific separation: the May 2026 Linzess label permits IBS-C from age 7 (145 mcg daily) and functional constipation from age 2 (72 mcg daily), while plecanatide is contraindicated below age 6 and should be avoided at ages 6 through 17. These are not interchangeable pediatric agents (Allergan, Inc., 2026; Salix Pharmaceuticals, Inc., 2024b).
Monitoring and Reassessment
- Document stool frequency and Bristol type, straining, incomplete evacuation, abdominal symptoms, rescue doses, and functional improvement, not bowel movement count alone.
- Assess adherence, water and fiber tolerance, medication-induced causes, and cost/insurance access before declaring treatment failure.
- Recheck electrolytes or kidney function when the chosen agent or comorbid condition creates an identifiable risk; do not order indiscriminate testing in uncomplicated functional constipation.
- Severe or worsening pain, vomiting, bleeding, or distension requires reassessment for obstruction, ischemia, impaction or another process instead of simply increasing the laxative dose.
- When soft stool still cannot be evacuated, consider a pelvic floor or outlet disorder rather than automatically escalating secretagogues.
Distinguish Stool Retention, Poor Propulsion, and Impaired Evacuation
At first assessment, distinguish low stool frequency from hard stool, excessive straining, incomplete evacuation, manual maneuvers and fecal seepage. Review medications (opioids, anticholinergics, iron, calcium-channel blockers), thyroid/neurologic contributors and hydration. Recurrent abdominal pain or discomfort with changes in stool form or frequency warrants evaluation for IBS using the current Rome V criteria; assign IBS subtype only after reviewing the predominant bowel pattern. Severe abdominal pain with distension, vomiting or absent flatus warrants obstruction evaluation before any secretagogue, bulk-forming agent or PAMORA is prescribed (Poole, 2026).
Fecal impaction can present as overflow liquid stool rather than improvement. When an impaction is suspected, evaluate for obstruction and plan appropriate evacuation before escalating maintenance laxatives. A patient with persistent straining and a sense of blockage despite soft stool needs assessment for a defecatory disorder; anorectal manometry and balloon-expulsion testing and pelvic floor biofeedback can be more appropriate than the next drug class (Staller et al., 2026).
Define an Adequate Trial and Escalate by Mechanism
In typical chronic idiopathic constipation, review an adequate gradual psyllium trial when appropriate, then an osmotic laxative such as PEG, with intermittent stimulant rescue when clinically justified. Guideline evidence is stronger for PEG than for many traditional OTC agents. If OTC therapies fail despite adequate dose and adherence, a secretagogue (linaclotide, plecanatide, lubiprostone) or 5-HT4 agonist (prucalopride) may be appropriate, selected by the approved indication, tolerability, access, and the specific product’s contraindications and precautions. Avoid magnesium-based products in significant kidney disease because of hypermagnesemia risk (Chang et al., 2023).
For opioid-induced constipation, establish that the opioid remains necessary and preventive laxative treatment is adequate. PAMORAs are for appropriate persistent OIC phenotypes, not bowel obstruction or all forms of constipation; agent-specific CYP interaction, kidney function, bowel-wall integrity and withdrawal precautions determine choice. Record opioid schedule, straining, complete spontaneous bowel movements, rescue use, pain, and adverse effects before selecting or switching treatment (Crockett et al., 2019).
Refractory Constipation Is a Diagnostic State, Not Simply More Drugs
The 2026 AGA practice update recommends evaluating most patients with chronic constipation using anorectal manometry with balloon expulsion and completing biofeedback for a demonstrated pelvic-floor disorder before declaring true refractory constipation. Verify secondary causes and an adequate trial of lifestyle and medicines; patients with documented slow transit and no ongoing defecatory disorder may be evaluated for selected advanced procedures. The need for specialized testing is not a reason to delay urgent evaluation of suspected obstruction, impaction with complications, or GI bleeding (Staller et al., 2026).
Decision pathway: Pattern / treatment
| Pattern / treatment | Expected benefit | Escalate or avoid when |
|---|---|---|
| Gradual psyllium trial | Bulks and softens stool; useful in suitable CIC phenotypes. | Avoid with suspected obstruction or inadequate fluid intake; may worsen marked bloating. |
| PEG or appropriate osmotic | Improves stool frequency and consistency. | Check response and diarrhea; magnesium salts may be unsafe in CKD. |
| Stimulant rescue (senna or bisacodyl) | Short-term acceleration of bowel movements; useful in selected regimens. | Assess cramping, cause of recurrent need and obstruction. |
| Secretagogue / prucalopride | Next mechanism after adequate OTC failure. | Verify the individual product’s indication, age restriction, diarrhea warning, renal precautions, and pregnancy information; do not generalize these limitations to the entire class. |
| PAMORA for persistent OIC | Targets peripheral opioid effect in eligible patients. | Avoid known/suspected obstruction; check CYP and kidney-specific labeling. |
| Outlet/defecatory disorder | Pelvic-floor assessment and biofeedback. | Another secretagogue alone will not correct dysfunctional evacuation. |
Applied Clinical Case and Prescribing Rationale
Scenario: A 66-year-old with CKD stage 4 receives chronic morphine for cancer pain, reports hard stools and new liquid seepage, with abdominal distension and vomiting. A caregiver asks for naloxegol. What comes first?
Reasoned response: Urgent evaluation for impaction or obstruction and volume/electrolyte complications comes before a PAMORA. If persistent OIC is later confirmed and obstruction excluded, verify the precise PAMORA indication and formulation: methylnaltrexone for advanced illness uses an indication-specific injection schedule, and renal/hepatic adjustments and drug interactions differ across agents. A bowel-movement count alone would miss overflow and incomplete evacuation (Poole, 2026).
High-Yield Distinctions
High-yield point
Patient A has longstanding hard stools and low fiber intake without red flags: PEG and selected dietary changes are appropriate initial options. Patient B takes oxycodone and fails regular osmotic/stimulant laxatives: consider a PAMORA after obstruction and interaction assessment. Patient C has soft stool but persistent severe straining and incomplete emptying: evaluate dyssynergia rather than adding a third laxative (Chang et al., 2023; Crockett et al., 2019).
Key clinical distinction: Chronic idiopathic constipation, IBS-C, outlet dysfunction, and opioid-induced constipation share symptoms but differ in evidence base, medication choice, and appropriate escalation.
Related YourDNP Resources
Pharmacology learning hub | Irritable Bowel Syndrome | Antiemetic Pharmacotherapy
Content last reviewed:
References
Allergan, Inc. (2026, May 21). Linzess (linaclotide) capsules [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09beda19-56d6-4a56-afdc-9a77b70b2ef3
Averitas Pharma, Inc. (2026, September 1). Movantik (naloxegol) tablets [U.S. prescribing information; current online label]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75698633-7903-4607-a08e-eae580212d7f
BioDelivery Sciences International, Inc. (2025, July 25). Symproic (naldemedine) tablets [U.S. prescribing information; current online label]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1a1256c-a1eb-4abe-ab1e-30e4711afd16
Chang, L., Chey, W. D., Imdad, A., Almario, C. V., Bharucha, A. E., Diem, S., Greer, K. B., Hanson, B., Harris, L. A., Ko, C., Murad, M. H., Patel, A., Shah, E. D., Lembo, A. J., & Sultan, S. (2023). American Gastroenterological Association–American College of Gastroenterology clinical practice guideline: Pharmacological management of chronic idiopathic constipation. American Journal of Gastroenterology, 118(6), 936–954. https://doi.org/10.14309/ajg.0000000000002227
Crockett, S. D., Greer, K. B., Heidelbaugh, J. J., Falck-Ytter, Y., Hanson, B. J., & Sultan, S. (2019). American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation. Gastroenterology, 156(1), 218–226. https://doi.org/10.1053/j.gastro.2018.07.016
Gordon, M., de Geus, A., Boruta, M., Banasiuk, M., Benninga, M., Borrelli, O., Darbari, A., Dore-Stites, D., Gould, M., Hawa, J., Jones, K., Kilgore, A., Mousa, H., Nurko, S., Thapar, N., Khlevner, J., Sinopoulou, V., & Tabbers, M. (2026). European Society for Paediatric Gastroenterology, Hepatology and Nutrition/North American Society for Pediatric Gastroenterology, Hepatology and Nutrition guidelines for treatment of functional constipation in children aged 0–18 years. Journal of Pediatric Gastroenterology and Nutrition, 83(2), 335–366. https://doi.org/10.1002/jpn3.70447
Poole, T. M. (2026). Functional gastrointestinal disorders. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 22). McGraw Hill.
Rome Foundation. (2026). Rome V criteria. https://theromefoundation.org/rome-v-criteria/
Salix Pharmaceuticals, Inc. (2024a, May). Relistor (methylnaltrexone) tablets and injection [U.S. prescribing information; current online label]. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c488fb7c-0a5b-487c-b452-996809d1cb99
Salix Pharmaceuticals, Inc. (2024b, April 4). Trulance (plecanatide) tablets [U.S. prescribing information; current online label]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe2895bf-71a6-493a-b0ca-e06b2dfefc82
Staller, K., Neshatian, L., Lembo, A., & Bharucha, A. E. (2026). AGA clinical practice update on evaluation and management of refractory constipation: Expert review. Clinical Gastroenterology and Hepatology, 24(2), 296–305. https://doi.org/10.1016/j.cgh.2025.09.031
U.S. Food and Drug Administration. (2026). Linzess (linaclotide) capsules [Prescribing information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/202811s023lbl.pdf